PMID- 30715609
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 1534-6269 (Electronic)
IS  - 1523-3790 (Linking)
VI  - 21
IP  - 2
DP  - 2019 Feb 4
TI  - Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should 
      Be Best Used?
PG  - 17
LID - 10.1007/s11912-019-0759-5 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to discuss the current 
      recommendations for the use of bispecific antibodies (bsAb) in hematologic 
      malignancies and explore the future in this field. RECENT FINDINGS: Bispecific 
      antibodies are molecules able to target two different antigen-binding sites: one 
      towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III 
      trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated 
      its efficacy for treating minimal residual disease (MRD+) and relapsed refractory 
      (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. 
      Currently, the only bispecific antibody (bsAb) approved for its use in 
      hematologic malignancies is blinatumomab. However, multiple trials are under 
      development not only to explore blinatumomab's clinical activity in other 
      neoplasia, such as lymphoma or multiple myeloma, but also to develop new 
      molecules against different antigens.
FAU - Demichelis-Gomez, Roberta
AU  - Demichelis-Gomez R
AD  - Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Avenida Vasco de Quiroga No. 15, Belisario Dominguez 
      Seccion XVI, Tlalpan, 14080, Mexico City, Mexico. robertademichelis@gmail.com.
FAU - Perez-Samano, Daniela
AU  - Perez-Samano D
AD  - Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Avenida Vasco de Quiroga No. 15, Belisario Dominguez 
      Seccion XVI, Tlalpan, 14080, Mexico City, Mexico.
FAU - Bourlon, Christianne
AU  - Bourlon C
AD  - Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Avenida Vasco de Quiroga No. 15, Belisario Dominguez 
      Seccion XVI, Tlalpan, 14080, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190204
PL  - United States
TA  - Curr Oncol Rep
JT  - Current oncology reports
JID - 100888967
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (Antineoplastic Agents, Immunological)
SB  - IM
MH  - Antibodies, Bispecific/immunology/*therapeutic use
MH  - Antineoplastic Agents, Immunological/immunology/*therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Hematologic Neoplasms/*drug therapy/immunology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Acute lymphoblastic leukemia
OT  - Antibodies
OT  - Antineoplastic agents
OT  - Bispecific antibodies
OT  - Immunotherapy
OT  - T-lymphocytes
EDAT- 2019/02/05 06:00
MHDA- 2020/06/23 06:00
CRDT- 2019/02/05 06:00
PHST- 2019/02/05 06:00 [entrez]
PHST- 2019/02/05 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
AID - 10.1007/s11912-019-0759-5 [pii]
AID - 10.1007/s11912-019-0759-5 [doi]
PST - epublish
SO  - Curr Oncol Rep. 2019 Feb 4;21(2):17. doi: 10.1007/s11912-019-0759-5.